Back to Acceleration Radar
STAASTAAR Surgical Company
Health Care · Ophthalmic Goods · Small
$22.61+0.53%
As of 23 Oct 2026Mkt cap $1.2B
Stage 13
AVOID
Fundamentals
4.5/75
Technical
8.3/15
Independent
12.8/90
GCAE viewFundamental /75 is below the Stage 13 acceptable-business floor
Price
- 1M
- +18.5%
- 3M
- −1.5%
- 6M
- −11.9%
- 1Y
- −9.2%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 323.0xHist median 87.0x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- —
- FCF yield
- —
Quality
- ROIC
- —
- Operating margin
- -4.0%
- FCF margin
- -16.7%
- Current ratio
- 4.5x
Growth
- Revenue growth
- −23.7%Latest FY YoY
- Revenue CAGR
- +1.0%
- EPS CAGR
- —
- FCF CAGR
- —
Capital
- Share-count trend
- +0.1%3Y annualised
- Net cash
- $115M
Annual trend
- CAGR 2021–2025
- +1.0%
- Latest · 2025
- $0B
- YoY
- −23.7%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- EARLY IGNITION
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- UNRESEARCHED · NEW RESEARCH
Key takeaway
Awaiting four-lens research.
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-11-04
- New current Route A/Route B candidate has no completed four-lens research.
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- approaching-support
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded